VGX 3400

Drug Profile

VGX 3400

Alternative Names: VGX-3400X; VGX™-3400

Latest Information Update: 18 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Pennsylvania
  • Developer GeneOne Life Science; Inovio Pharmaceuticals
  • Class DNA vaccines; Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype

Most Recent Events

  • 16 May 2012 Final immunogenicity data from a phase I extension trial in Influenza-A virus subtype H5N1 infections (prevention) released by Inovio Pharmaceuticals
  • 16 May 2012 Inovio Pharmaceuticals completes a phase I trial in Influenza-A virus H5N1 subtype infections (Prevention, In volunteers) in USA (9137178; NCT01142362 and NCT01403155)
  • 17 Nov 2011 Interim immunogenicity and adverse events data from a phase I extension trial for Influenza A virus H5N1 subtype infections (Prevention, In volunteers) presented at the 5th WHO Meeting on Influenza Vaccines that Induce Broad Spectrum and Long-Lasting Immune Responses
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top